ARA-290
Not medical advice. PepTutor summarizes fallible research and community signal for trained practitioners; some compounds are research-only, unapproved, controlled, jurisdiction-dependent, or labeled not for human consumption.
ARA-290 is a niche nerve-repair peptide for small fiber neuropathy, neuropathic pain, and dysautonomia-adjacent neuroinflammation, with its strongest case when symptoms can be tracked against SFNSL, PainDetect, or corneal nerve measures.
Physiologic safety looks relatively light in trials, but this remains a niche injection/reconstitution compound where sourcing, sterility, and measurable neuropathy endpoints matter.
ARA-290 is a niche nerve-repair peptide for small fiber neuropathy, neuropathic pain, and dysautonomia-adjacent neuroinflammation, with its strongest case when symptoms can be tracked against SFNSL, PainDetect, or corneal nerve measures.
No hematopoietic or prothrombotic signal in Phase 2 trials, and adverse events were comparable to placebo. The practical risks are research-only sourcing, fragile PBS reconstitution, short post-reconstitution stability, and mild transient fatigue or flu-like sensations reported in the first 1-3 days.
The only compound with Phase 2 RCT evidence of measurable small fiber nerve regeneration in humans — not analgesia, not symptom masking, but documented regrowth of corneal nerve fibers by confocal microscopy. For treatment-refractory neuropathic pain (SFN, T2DM neuropathy, Lyme, ME/CFS), this positions it in a different category from gabapentin, pregabalin, and duloxetine.
High for neuropathic pain and SFN — community signal strongly positive with good alignment to Phase 2 trial outcomes. Community consensus: rapid pain relief within 1-2 weeks, structural nerve regeneration signal at 3-4 months.
Intro
ARA-290 (also called Cibinetide) is an 11-amino acid cyclic peptide reverse-engineered from the helix B surface of erythropoietin.
Araim Pharmaceuticals designed it to selectively activate the innate repair receptor (IRR) — a heteromeric complex of the EPO receptor (EPOR) and the beta-common receptor (CD131) — without triggering the homodimeric EPOR responsible for red blood cell production. This pharmacological split is the compound's defining property: all the tissue-protective effects of EPO, none of the hematopoietic or prothrombotic risks.
The IRR is upregulated specifically at sites of injury and inflammation — peripheral nerves, spinal cord microglia, kidney, pancreatic islets, vascular endothelium. ARA-290's binding initiates two converging pathways: PI3K/Akt (suppressing NF-kB-driven inflammatory cytokine production and activating eNOS) and JAK2/STAT5 (driving anti-apoptotic gene transcription). Together, these reprogram a pro-inflammatory, tissue-damaging environment into one of healing and repair — not by suppressing immune function broadly, but by activating a targeted repair signal where the pathology is.
ARA-290 completed multiple Phase 2 clinical trials with positive results: a double-blind randomized pilot in sarcoidosis small fiber neuropathy (Molecular Medicine 2012), a Phase 2 study in T2DM with neuropathy (Molecular Medicine 2015), and a 4-week open-label Phase 2 trial in rheumatoid arthritis (ARD 2013). Across all trials, ARA-290 showed adverse event profiles comparable to placebo. Most significantly, both neuropathy trials documented measurable increases in corneal nerve fiber density by confocal microscopy — structural nerve regeneration in humans, not just symptomatic relief. Phase 3 was never initiated; Araim Pharmaceuticals, a 7-person startup, could not secure the funding required despite the positive Phase 2 package.
Observed Effects
Confirmed in Phase 2 RCTs: - Sarcoidosis SFN (n=22, 28 days): significant improvement in neuropathic and autonomic symptoms on the Small Fiber Neuropathy Screening List questionnaire; corneal nerve fiber area increased by 23% (confocal microscopy); no significant adverse events. - T2DM neuropathy (28 days): HbA1c and lipid profiles improved throughout 56-day observation period; PainDetect neuropathic symptom scores significantly improved; subjects with CNFD >1 SD below normal showed significant CNFD increase vs no change in placebo. 'Pain attacks' and 'burning sensations' trended toward improvement. - Autonomic symptoms improved in the sarcoidosis trial — relevant to dysautonomia/POTS populations where SFN has an autonomic component. - Rheumatoid arthritis (4-week Phase 2 open-label): primary endpoints met on inflammatory markers.
Mechanistically plausible, not yet RCT-confirmed: - Pancreatic islet protection in transplantation (mouse model): caspase 3/7 suppression, blood glucose improved, hepatic pro-inflammatory cytokines reduced. - Wound healing acceleration in diabetic animal model (preprint). - ANA marker reduction (single community case report). - PEM and CFS symptom improvement in ME/CFS patients (community reports, no controlled data).
Field Reports
First-person reports from the chronic illness community:
Chronic-illness community report: Neuropathy reduced from 7-8/10 to 2/10 within hours of injection. Reports a group of users experiencing improvements in neuropathy, POTS, CFS, and PEM. Notes blood glucose lowering and an anecdotal ANA marker reduction.
ME/CFS community report: Presented ARA-290 as producing results comparable to IVIG for SFN patients at a fraction of the cost (~$160-200/month vs $10,000-30,000/IVIG course). The cost-access framing resonated strongly in a community where IVIG access is difficult and expensive.
GLP-1 community users with T2DM: Onset of pain relief within 1-2 weeks of starting at 4mg daily, incremental improvement over 2-3 months. Several users stack with semaglutide or tirzepatide for concurrent metabolic and neuropathic treatment.
Women-focused peptide community reports include a chronic nerve-pain case and practical handling observations.
Timeline consensus across reports: - Week 1-2: anti-inflammatory phase, burning/tingling reduction (TRPV1 modulation) - Week 4-8: pain signaling improvement - Month 3-4: structural nerve regeneration potentially measurable by corneal confocal microscopy
Safety reports across all community sources: uniformly clean — no hematological effects, no immune suppression, no injection site complications beyond standard discomfort. Mild transient fatigue in first 1-3 days reported by some users.
Community Consensus
ARA-290 occupies an unusual position in the peptide landscape: it has stronger human clinical trial evidence than most research compounds (multiple Phase 2 RCTs, peer-reviewed in major journals) but remains unknown to most of the performance peptide community because its indications are specific to neuropathic disease rather than enhancement.
The community that knows ARA-290 well is the chronic illness population — chronic-illness, GLP-1, and women-focused peptide communities. These communities adopted ARA-290 based directly on the clinical trial literature, which is unusual for a research peptide. The community's usage patterns, dosing, and outcome reports closely match the trial protocols.
The practical preparation-instability issue is a community-discovered finding not addressed in clinical trial protocols, which used pharmaceutical-grade formulations. This is a genuine value-add from community experience that isn't in the academic literature.
ARA-290's Phase 2 success and Phase 3 absence is well-understood in the community: Araim Pharmaceuticals was a 7-person startup that completed the Phase 2 package but could not secure the $50-100M+ required for Phase 3. The scientific evidence is genuinely strong; the compound's research-only status is a commercial/regulatory artifact, not a scientific verdict.
Risks & Monitoring
ARA-290 has the cleanest adverse event profile of any neuropathy compound reviewed in multiple clinical trials:
Community-reported (not verified in trials): - Mild fatigue or flu-like sensations in the first 1-3 days, attributed to immune remodulation. Transient, self-resolving. - No injection site complications beyond standard injection discomfort.
No dose-related toxicity has been documented at 1-8mg SC daily. The IRR's site-selective expression (upregulated at injury sites) provides a natural safety mechanism — ARA-290 exerts its effects preferentially where pathology is present, not systemically across healthy tissue.
For Women
Monitoring Panels
REQUIRED is a real safety gate. RECOMMENDED is the prudent default. OPTIONAL covers symptoms, risk factors, or tighter tracking.
The primary clinical trial endpoint for ARA-290's nerve regeneration effect. Baseline CNFD establishes whether the patient has sufficient SFN severity to show response; subjects with CNFD >1 SD below normal showed the strongest regeneration signal. Requires a specialist ophthalmology setup.
The primary symptom outcome measure from the sarcoidosis SFN RCT. Self-administered, validates subjective neuropathic and autonomic symptom burden at baseline, and tracks whether ARA-290 is doing anything measurable. Free, no lab required, but not a safety gate.
Used in the T2DM Phase 2 trial as the neuropathic pain endpoint. Tracks quality and severity of neuropathic pain (burning, tingling, allodynia). Pair with SFNSL for comprehensive neuropathy monitoring.
ARA-290 improved HbA1c and lipid profiles in the T2DM trial. Useful baseline for any user with diabetes or metabolic neuropathy to track the metabolic component alongside nerve regeneration.
Confirms no hematopoietic effect — hematocrit, hemoglobin, and RBC count should remain unchanged from baseline. Provides reassurance that the compound is not activating the erythropoietic pathway.
Provides an objective baseline for systemic inflammation. Useful for tracking anti-inflammatory response in chronic inflammatory conditions (Lyme, ME/CFS, RA, sarcoidosis).
ARA-290 improved lipid profiles in T2DM trial subjects. Useful baseline if using for metabolic neuropathy or metabolic syndrome context.
Avoid With
Do not combine ARA-290 with the following. Sorted highest-severity first.
Why:ARA-290 and EPO act on overlapping receptor systems. While ARA-290 is selective for IRR and not the erythropoietic EPOR homodimer, co-administration with EPO for performance enhancement creates an unnecessary redundancy and theoretical interaction with shared receptor components.
What to do:No documented case reports of harm; caution is mechanistically derived. ARA-290 was specifically engineered to avoid EPO's hematopoietic effects — stacking with EPO defeats this purpose and introduces polycythemia risk from the EPO component.
Why:Not a true pharmacological conflict. Naming similarity between ARA-290 and PDA causes community confusion. These are completely different compounds with different mechanisms. Ensure you have the correct compound before use.
What to do:ARA-290 = IRR agonist, EPO-derived, 11-aa cyclic peptide. PDA = arginate form of a BPC-157 derivative. The disambiguation is important to avoid purchasing or dosing the wrong compound.
Protocols By Goal
Sarcoidosis/autoimmune SFN: - 4mg SC daily x 28 days (mirrors the Phase 2 RCT protocol) - Monitor SFNSL questionnaire, autonomic symptoms, and corneal confocal microscopy if available - Consider 3x weekly maintenance if response achieved after 28-day induction - Stack consideration: ARA-290 + low-dose NAC for additional anti-inflammatory and oxidative stress support
T2DM peripheral neuropathy: - 4mg SC daily x 28 days; continue to day 56 to capture HbA1c and CNFD improvement - Stack with ongoing GLP-1 agonist for concurrent metabolic control (no known negative interaction) - Monitor HbA1c, PainDetect score, and CNFD if accessible
ME/CFS / POTS / Lyme-associated SFN: - 4mg SC daily x 28 days; assess symptom response (neuropathy, POTS symptoms, PEM) - This is community-derived, not clinical trial-backed for these specific diagnoses - Lower starting dose (1-2mg) may be preferred for sensitive patients; titrate up
Neuropathic pain (various etiologies, including post-chemo): - 4mg SC daily x 28 days standard; 3x weekly if cost is a constraint - Stack with BPC-157 (200-500mcg SC 2x daily) if structural tissue repair is also indicated
Longevity / anti-inflammaging: - Speculative use case; no controlled data - 3x weekly low-dose maintenance used by community for chronic neuroinflammation management
Dosing Details
Standard clinical-trial-derived protocol: 4 mg SC daily for 28 days, matching Phase 2 trial protocols.
Subcutaneous administration is the studied route; no oral or intranasal route has comparable support. Preparation and storage mechanics are not standardized for readers and should not be treated as injection or compounding guidance.
Dose-ranging: 1-8 mg per dose has been explored in clinical trials and community reports. 4 mg is the established effective dose from Phase 2 trials; doses above 4 mg show similar efficacy in available data, suggesting a plateau effect. Three-times-weekly 4 mg appears in maintenance or cost-managed community reports, but it has less evidence than daily use.
Cycles: 28-day induction cycle, then assess response. Long-term users with chronic neuropathy sometimes continue three-times-weekly maintenance for 3-6 months. No established washout requirement between cycles.
Pharmacokinetics: plasma half-life is approximately 2 minutes, with subcutaneous depot exposure estimated around 11 hours. The depot duration explains why once-daily dosing can produce sustained benefit despite short plasma half-life.
Stacks & Alternatives
Complementary mechanisms — ARA-290 targets IRR/neuroinflammation; BPC-157 targets VEGF/angiogenesis/structural repair. Covers both the neuroinflammatory and structural dimensions of neuropathy repair. No negative interaction.
For T2DM neuropathy users; concurrent metabolic glucose control plus direct nerve repair. ARA-290 improved HbA1c and CNFD in T2DM trial; GLP-1 adds metabolic management. Mechanistically synergistic.
Antioxidant support for peripheral nerve health; complements ARA-290's NF-kB suppression with additional oxidative stress reduction. Standard companion in diabetic neuropathy protocols.
Mitochondrial antioxidant used alongside ARA-290 in diabetic neuropathy protocols for complementary nerve protection via oxidative stress pathway.
Tissue repair companion with broader vascular and structural effects via G-actin binding and angiogenesis. No known interaction with ARA-290; covers vascular component of neuropathy.
Standard neuropathy supportive supplements. B12 deficiency is a common neuropathy driver; ensuring sufficiency is a prerequisite before attributing response to ARA-290. No interaction.
Alternatives
Stack Cost
ARA-290 is low physiological tax when used for a real neuropathy/SFN indication, but moderate practical tax from injection handling, PBS reconstitution, specialist outcome tracking, research-only sourcing, and limited long-term data beyond short Phase 2 windows.
The article requires subcutaneous injection and has strict handling/stability constraints. Those handling constraints are the main practical burden.
The article states no required lab monitoring because the Phase 2 safety profile is clean. SFNSL, PainDetect, corneal confocal microscopy, and condition-specific metabolic or inflammatory markers are mainly response-tracking tools, not safety gates.
The article frames ARA-290 as research-only, not FDA-approved, with no Phase 3 program and a typical 4 mg daily protocol around $160-200 per month. Access depends on peptide product channels rather than a normal prescription channel.
The article lists no established negative interactions and describes clean Phase 2 safety, but it flags caution with EPO or EPO analogs because of overlapping receptor systems and the risk of inheriting EPO's hematopoietic/polycythemia burden.
- ·Reserve ARA-290 for users with a plausible neuropathic, SFN, dysautonomia, diabetic neuropathy, Lyme, ME/CFS, sarcoidosis, or neuroinflammatory indication rather than treating it as a general wellness peptide.
- ·Use clean peptide handling as a hard capacity rule: PBS reconstitution, short post-reconstitution storage, correct cold chain, and confirmation that the vial is ARA-290 rather than a similarly named peptide.
- ·Do not stack with EPO or hematopoietic EPO analogs unless a clinician is deliberately managing that therapy; ARA-290 was chosen to avoid the red-cell and thrombosis burden of EPO.
- ·Track symptom scores before adding more repair peptides, GLP-1s, or antioxidants so any change can be attributed rather than lost inside a broad chronic-illness stack.
- ·Subcutaneous injection supplies and sterile technique.
- ·PBS reconstitution and strict cold-storage workflow.
- ·Baseline and follow-up SFNSL/PainDetect symptom scoring.
- ·CBC documentation if the user wants to verify the expected absence of hematopoietic effect.
- ·Corneal confocal microscopy when available for structural SFN tracking.
The article describes a clean safety profile, no hematopoietic or prothrombotic signal, no hormonal suppression, and no taper requirement. The beginner caveat is practical rather than physiological: ARA-290 is still a research-only injectable with condition-specific endpoints, fragile reconstitution, and a narrow evidence-backed use case.
- ·Using it as a vague anti-inflammatory or longevity peptide without neuropathy-specific endpoints.
- ·Unable to manage PBS reconstitution, freezer storage, and 24-hour post-reconstitution handling.
- ·Currently using EPO or another hematopoietic agent.
- ·Pregnant or attempting pregnancy, given the research-only status and lack of pregnancy safety data.
The article does not describe hormonal suppression, rebound physiology, taper requirements, or withdrawal. ARA-290 has a very short plasma half-life and a finite tissue-exposure window, so stopping is mechanically simple.
- ·Neuropathic pain, burning, dysautonomia, or PEM symptoms may drift back toward baseline if the compound was providing active symptom control.
- ·Users may misread loss of benefit as withdrawal rather than return of the underlying disease process.
- ·Long-term maintenance users may need a symptom-tracking reset before deciding whether to resume.
Define the target condition and measurement method before starting. If no neuropathy or neuroinflammation endpoint exists, choose a simpler support compound rather than escalating ARA-290.
Use conservative handling, discard questionable solution, and do not increase dose to compensate for degraded material.
Confirm the compound identity before use. Prefer products with COAs and third-party testing; do not infer identity from peptide naming similarity.
Add ARA-290 as a measured intervention with a 28-day induction window, then layer complementary tools only after a response baseline is clear.
The article says ARA-290 was engineered to keep EPO-like tissue repair while avoiding red-cell production; stacking with EPO reintroduces the polycythemia and thrombosis burden ARA-290 avoids.
The womenConsiderations block notes insufficient pregnancy data despite no expected reproductive endocrine effect. Research-only peptides should be avoided here without clinician oversight.
The compound is injectable-only and the article gives unusually specific PBS, cold-storage, and short-stability constraints.
The article explicitly flags PDA naming confusion and limited product-quality assurance.
Practical Setup
Handling and stability: ARA-290 behaves differently from many small peptides and has reported preparation-instability issues.
Prepared-solution stability may be short, so questionable or degraded-looking material should be discarded rather than dose-escalated. Specific compounding mechanics are intentionally omitted.
Product identity: ARA-290 is less common than BPC-157 or TB-500 in the peptide landscape. Prioritize identity/purity documentation and confirm the product is not a similar-sounding compound such as PDA/pentadecapeptide arginate.
Cost: around $160-200/month for a 4mg daily protocol is a commonly cited range. Some users reduce to three-times-weekly dosing for cost management while trying to maintain effect.
Patient selection: Evidence strongest for patients with established SFN (CNFD significantly below normal) - the Phase 2 trial showed the regeneration effect specifically in subjects with more severe baseline nerve damage. Early or subclinical neuropathy may respond less dramatically.
Sensitivity: Patients with ME/CFS or chronic immune dysregulation may be more sensitive to the immune modulation effect. Some reports start at 1-2mg and titrate to 4mg over 1-2 weeks, but this remains non-standardized.
No oral route: ARA-290 has no oral bioavailability. Subcutaneous injection is the only established route. Intranasal and sublingual routes have no evidence and are not community-established.
Monitoring: No required lab monitoring given clean safety profile. CBC at baseline can document no hematopoietic effect. SFNSL and PainDetect questionnaires are the best self-monitoring tools.
Mechanism Deep Dive
ARA-290 is a selective agonist of the innate repair receptor (IRR), a heteromeric complex of the EPO receptor (EPOR) and the beta-common receptor (CD131/βcR).
This is pharmacologically distinct from the homodimeric EPOR that drives erythropoiesis — the critical selectivity that eliminates EPO's hematopoietic and prothrombotic effects.
IRR expression is upregulated specifically at sites of injury and inflammation: injured peripheral nerves, activated spinal cord microglia, stressed kidney tubular cells, inflamed pancreatic islets, ischemic vascular endothelium. This conditional, injury-site-selective expression provides a natural targeting mechanism — ARA-290 acts where the receptor is accessible.
Upon IRR binding, two parallel pathways converge:
1. PI3K/Akt pathway: Phosphorylates and activates Akt, which suppresses NF-kB-mediated transcription of pro-inflammatory cytokines (IL-6, IL-12, TNF-alpha, MCP-1, MIP-1beta). Simultaneously phosphorylates endothelial NOS (eNOS), generating NO for vascular protection. Net effect: cytokine storm suppression + vascular stabilization.
2. JAK2/STAT5 pathway: Activates JAK2, which phosphorylates STAT5, driving transcription of anti-apoptotic and cytoprotective genes. Net effect: cell survival, anti-apoptosis, tissue preservation.
Pain pathway: ARA-290 modulates TRPV1 (transient receptor potential vanilloid 1) channel activity via IRR signaling, integrating the immune system with nociceptive processing. This TRPV1 interaction explains the rapid (hours) pain relief before structural nerve regeneration can account for it.
Neuroinflammation: In the spinal cord, ARA-290 suppresses microglial activation — a key driver of central sensitization and chronic neuropathic pain chronification. The beta-common receptor knockout data (no anti-allodynic effect in knockout mice) confirms the IRR-dependence of this central effect.
Macrophage reprogramming: ARA-290 directly suppresses macrophage secretion of IL-6, IL-12, and TNF-alpha in ex vivo assays — macrophage-driven neuroinflammation is a major contributor to SFN and peripheral neuropathy chronification.
The mechanistic consequence: ARA-290 reprograms the injured tissue environment from pro-inflammatory/tissue-damaging to healing/repair — not by suppressing immune function globally, but by activating a targeted repair signal at the injury site. This is the mechanistic basis for structural nerve fiber regeneration observed in the clinical trials.
Evidence Index
Quantitative claims trace to these source studies. Population, dose, and study type matter — claims from HIV-lipodystrophy trials don't transfer cleanly to healthy adults; data from supraphysiologic doses doesn't apply at TRT.
ARA-290 significantly improved neuropathic and autonomic symptoms in sarcoidosis SFN patients with 23% increase in corneal nerve fiber area
Double-blind randomized pilot (Phase 2); Molecular Medicine 2012; Brines/Dahan/Cerami. Primary endpoints met. Landmark nerve regeneration finding.
ARA-290 improved HbA1c, lipid profiles, and neuropathic symptom scores in T2DM patients; CNFD increased in severely neuropathic subgroup
Phase 2 randomized controlled trial; Molecular Medicine 2015 (PMC4365069); Brines et al. CNFD increase significant in subjects with CNFD >1 SD below normal.
ARA-290 showed safety and primary endpoint efficacy in a 4-week open-label Phase 2 trial in active rheumatoid arthritis
Phase 2 open-label (no placebo control); EULAR ARD SAT0116 abstract; extends evidence to autoimmune joint disease
ARA-290 produced rapid and long-term relief of mechanical and cold allodynia in sciatic nerve injury mice; no effect in beta-common receptor knockout animals
PAIN Reports review paper; knockout data confirms IRR-dependence of anti-allodynic effect
ARA-290 protected pancreatic islets from cytokine-induced apoptosis and improved blood glucose in marginal islet transplantation model
Transplantation 2016; Watanabe/Brines et al.; blood glucose p<0.001 vs control; caspase 3/7 significantly suppressed
ARA-290 suppresses macrophage secretion of IL-6, IL-12, and TNF-alpha in ex vivo assays
Transplantation 2016; ex vivo macrophage assay data supporting the anti-inflammatory mechanism
ARA-290 neuropathy to 2/10 from 7-8/10 within hours; group improvements in neuropathy, POTS, CFS, PEM
Chronic-illness community multi-user report; not controlled
Not medical advice. PepTutor summarizes fallible research and community signal for trained practitioners; some compounds are research-only, unapproved, controlled, jurisdiction-dependent, or labeled not for human consumption.